CD274 and cancer: The micelles were demonstrated to be capable of achieving antitumor effects in a synergistic manner with anti-PD-1 via the promotion of the ICD process; further, they decreased both the number of intramural MSDCs and PD-L1 expression on cancer cells, stimulating the future translation of the Epi/m plus anti-PD-1 combination into clinical trials.